Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: HYP063
MIFTS: 52

Hypersplenism

Categories: Blood diseases, Immune diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Hypersplenism

About this section

MalaCards integrated aliases for Hypersplenism:

Name: Hypersplenism 12 54 44 15 17 70 32
Hypersplenia 12

Classifications:

MalaCards categories:
Anatomical: Immune diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:6376
ICD9CM 34 289.4
MeSH 44 D006971
NCIt 50 C34714
SNOMED-CT 67 154839008
ICD10 32 D73.1
UMLS 70 C0020532
Sources

Summaries for Hypersplenism

About this section
MalaCards based summary : Hypersplenism, also known as hypersplenia, is related to splenic infarction and hemolytic anemia. An important gene associated with Hypersplenism is F2 (Coagulation Factor II, Thrombin), and among its related pathways/superpathways are ERK Signaling and PEDF Induced Signaling. The drugs tannic acid and Dalteparin have been mentioned in the context of this disorder. Affiliated tissues include spleen, bone marrow and liver, and related phenotypes are immune system and cellular

Wikipedia : 73 Splenomegaly is an enlargement of the spleen. The spleen usually lies in the left upper quadrant (LUQ)... more...

Sources

Related Diseases for Hypersplenism

About this section

Diseases related to Hypersplenism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 574)
# Related Disease Score Top Affiliating Genes
1 splenic infarction 30.4 SERPINC1 GPT F2 ALB
2 hemolytic anemia 30.4 IL4 IFNG F2 EPO CSF3
3 portal hypertension 30.3 TLR4 THPO GPT F2 CD4 ALB
4 splenic tuberculosis 30.3 F2 CD4 ALB
5 paralytic ileus 30.2 GPT F2 ALB
6 hemosiderosis 30.2 GPT EPO ALB
7 splenic abscess 30.2 GPT F2 CSF3 CD4 ALB
8 hepatic encephalopathy 30.1 GPT F2 ALB
9 peritonitis 30.1 TLR4 IL4 F2 ALB
10 endocarditis 30.1 SERPINC1 IFNG F2 ALB
11 esophageal varix 30.0 THPO SERPINC1 GPT F2 ALB
12 splenic sequestration 30.0 THPO F2 EPO CD4
13 schistosomiasis 30.0 IL4 IFNG GPT F2 ALB
14 q fever 30.0 TLR4 IL4 IFNG
15 hepatic coma 30.0 SERPINC1 GPT F2 ALB
16 budd-chiari syndrome 30.0 SERPINC1 F2 ALB
17 biliary atresia 30.0 IFNG GPT F2 ALB
18 hepatoportal sclerosis 30.0 GPT F2
19 purpura 29.9 THPO SERPINC1 IL4 IFNG F2
20 peripheral vascular disease 29.9 SERPINC1 F2 EPO ALB
21 liver cirrhosis 29.9 TLR4 THPO SERPINC1 IFNG GPT F2
22 acquired immunodeficiency syndrome 29.8 IFNG EPO CSF2 CD4 ALB
23 hepatorenal syndrome 29.8 GPT F2 ALB
24 brucellosis 29.8 TLR4 IL4 IFNG
25 severe combined immunodeficiency 29.8 IL4 IFNG CSF3 CSF2
26 dysentery 29.8 GPT CD4 ALB
27 pancytopenia 29.8 THPO IFNG FOXP3 EPO CSF3 CSF2
28 adult t-cell leukemia 29.7 IL4 FOXP3 CD4
29 hepatitis b 29.7 TLR4 IFNG GPT F2 ALB
30 beta-thalassemia 29.7 SERPINC1 GPT F2 EPO CD4
31 candidiasis 29.6 TLR4 IL4 IFNG CSF2
32 aphthous stomatitis 29.6 TLR4 IL4 IFNG CSF2
33 neutropenia 29.6 THPO GPT EPO CSF3 CSF2 ALB
34 cholangitis 29.6 TLR4 GPT F2 ALB
35 stomatitis 29.5 IL4 IFNG CSF3 CSF2 CD4
36 bacterial infectious disease 29.5 TLR4 IFNG CSF3 CSF2 CD4
37 abdominal tuberculosis 29.5 IFNG GPT F2 CD4 ALB
38 toxic shock syndrome 29.4 TLR4 SERPINC1 LTA IL4 IFNG
39 t-cell lymphoblastic leukemia/lymphoma 29.4 REL LTA FOXP3 CD4
40 polycythemia 29.4 THPO SERPINC1 F2 EPO
41 myelofibrosis 29.4 THPO EPO CSF3 BMP6
42 primary biliary cholangitis 29.3 GPT FOXP3 F2 CD4 ALB
43 sickle cell anemia 29.3 GPT F2 EPO CSF3 CSF2 BMP6
44 autoimmune hepatitis 29.3 IL4 GPT FOXP3 F2 ALB
45 thrombocytosis 29.2 THPO SERPINC1 F2 EPO CSF3 CSF2
46 myeloproliferative neoplasm 29.2 THPO EPO CSF3 CSF2
47 hemoglobinuria 29.2 THPO SERPINC1 F2 EPO CSF3
48 paroxysmal nocturnal hemoglobinuria 29.2 THPO SERPINC1 F2 EPO CSF3
49 acute leukemia 29.2 THPO EPO CSF3 CSF2
50 syphilis 29.2 IFNG GPT FOXP3 F2 CD4 ALB

Comorbidity relations with Hypersplenism via Phenotypic Disease Network (PDN): (show all 12)


Acquired Thrombocytopenia Active Peptic Ulcer Disease
Acute Cystitis Alcoholic Liver Cirrhosis
Chronic Congestive Splenomegaly Deficiency Anemia
Heart Disease Hepatic Encephalopathy
Iron Deficiency Anemia Neutropenia
Portal Hypertension Primary Thrombocytopenia

Graphical network of the top 20 diseases related to Hypersplenism:



Diseases related to Hypersplenism
Sources

Symptoms & Phenotypes for Hypersplenism

About this section

MGI Mouse Phenotypes related to Hypersplenism:

46 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 10.38 ALB CD4 CSF2 CSF3 EGF EPO
2 cellular MP:0005384 10.34 ALB CD4 CSF2 EPO F2 FOXP3
3 growth/size/body region MP:0005378 10.34 BMP6 CD4 CSF2 EGF F2 FOXP3
4 homeostasis/metabolism MP:0005376 10.34 ALB CD4 CSF2 EPO F2 FOXP3
5 hematopoietic system MP:0005397 10.32 CD4 CSF2 CSF3 EPO FOXP3 IFNG
6 cardiovascular system MP:0005385 10.31 ALB CSF2 EPO F2 FOXP3 IFNG
7 endocrine/exocrine gland MP:0005379 10.24 ALB CD4 CSF2 EGF F2 FOXP3
8 integument MP:0010771 10.23 CD4 CSF2 CSF3 EGF EPO F2
9 mortality/aging MP:0010768 10.22 ALB CD4 CSF2 EPO F2 FOXP3
10 digestive/alimentary MP:0005381 10.2 ALB CD4 EGF F2 FOXP3 IFNG
11 liver/biliary system MP:0005370 10.13 ALB EPO FOXP3 IFNG IL4 LTA
12 normal MP:0002873 10.11 ALB CD4 EGF EPO F2 FOXP3
13 renal/urinary system MP:0005367 9.92 ALB CSF2 CSF3 FOXP3 IFNG IL4
14 reproductive system MP:0005389 9.91 BMP6 CSF2 EGF F2 FOXP3 IFNG
15 respiratory system MP:0005388 9.85 CSF2 EPO F2 FOXP3 IFNG IL4
16 skeleton MP:0005390 9.65 BMP6 CSF2 EPO F2 GPT IFNG
17 vision/eye MP:0005391 9.28 EGF FOXP3 IFNG IL4 LTA PIK3R1
Sources

Drugs & Therapeutics for Hypersplenism

About this section

Drugs for Hypersplenism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 33)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
tannic acid Approved Phase 4 1401-55-4
2
Dalteparin Approved Phase 4 9005-49-6
3
Heparin Approved, Investigational Phase 4 9005-49-6 772 9812414
4
Dipyridamole Approved Phase 4 58-32-2 3108
5
Warfarin Approved Phase 4 81-81-2 54678486 6691
6
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
7
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
8
Nadroparin Approved, Investigational Phase 4
9
Tinzaparin Approved Phase 4 9041-08-1, 9005-49-6 25244225
10 Liver Extracts Phase 4
11 Analgesics, Non-Narcotic Phase 4
12 Vasodilator Agents Phase 4
13 Anticoagulants Phase 4
14 Analgesics Phase 4
15 Fibrinolytic Agents Phase 4
16 Antirheumatic Agents Phase 4
17 Cyclooxygenase Inhibitors Phase 4
18 Heparin, Low-Molecular-Weight Phase 4
19 calcium heparin Phase 4
20 Phosphodiesterase Inhibitors Phase 4
21 Antipyretics Phase 4
22 Platelet Aggregation Inhibitors Phase 4
23 Anti-Inflammatory Agents Phase 4
24 Anti-Inflammatory Agents, Non-Steroidal Phase 4
25 Calcium, Dietary Phase 4
26
Calcium Nutraceutical Phase 4 7440-70-2 271
27
Valproic acid Approved, Investigational Phase 1, Phase 2 99-66-1 3121
28 Neurotransmitter Agents Phase 1, Phase 2
29 Psychotropic Drugs Phase 1, Phase 2
30 Anticonvulsants Phase 1, Phase 2
31
Somatostatin Approved, Investigational 38916-34-6, 51110-01-1 53481605
32 Adrenergic beta-Antagonists
33 Sclerosing Solutions

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Warfarin Anticoagulation for Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic Splenectomy Unknown status NCT02238444 Phase 4 Warfarin;Dipyridamole;Aspirin;Low Molecular Weight Heparin
2 Pilot (Phase I-II) Study of Valproic Acid (Depakote) for the Treatment of the Autoimmune Lymphoproliferative Syndrome (ALPS) Completed NCT00605657 Phase 1, Phase 2 Valproic Acid
3 Comparative Study of Microwave Ablation and Partial Splenic Embolization in the Management of Hypersplenism Unknown status NCT02261584
4 Hypersplenism in Patients With Liver Cirrhosis and Portal Hypertension: Prevalence, Pattern, Correlations, and Therapy Unknown status NCT03269877
5 Multicentric Retrospective Case Control Study of the Impact of Hypersplenism and Splenectomy on Hepatocarcinogenesis in Patients With Posthepatitic Cirrhosis Unknown status NCT01201655
6 The Treatment of Gastroesophageal Varices Accompanied With Splenomegaly or Hypersplenism of Hepatocirrhosis and Portal Hypertension Unknown status NCT02778425
7 EUS-guided Partial Splenic Embolization in Combination With EUS-guided Treatment of Varices for Patients With Portal Hypertension Recruiting NCT04692805 cyanoacrylate glue

Search NIH Clinical Center for Hypersplenism

Cochrane evidence based reviews: hypersplenism

Sources

Genetic Tests for Hypersplenism

About this section
Sources

Anatomical Context for Hypersplenism

About this section

MalaCards organs/tissues related to Hypersplenism:

40
Spleen, Bone Marrow, Liver, Kidney, Myeloid, Neutrophil, Breast
Sources

Publications for Hypersplenism

About this section

Articles related to Hypersplenism:

(show top 50) (show all 2135)
# Title Authors PMID Year
1
Partial splenic embolization as pretreatment for antiviral therapy in hepatitis C virus infection. 54 61
16215425 2005
2
Platelet count increase following phlebotomy in iron overloaded patients with liver cirrhosis. 54 61
12911944 2003
3
Role of elevated platelet-associated immunoglobulin G and hypersplenism in thrombocytopenia of chronic liver diseases. 61 54
12753144 2003
4
Serum thrombopoietin levels are linked to liver function in untreated patients with hepatitis C virus-related chronic hepatitis. 61 54
12399221 2002
5
Role of plasma thrombopoietin level in thrombocytopenia of postoperative biliary atresia patients. 61 54
12149701 2002
6
Thrombocytopenia associated with liver cirrhosis and hepatitis C viral infection: role of thrombopoietin. 54 61
11100362 2000
7
Thrombopoietin levels in serum and liver tissue in patients with chronic viral hepatitis and hepatocellular carcinoma. 54 61
11787473 2000
8
Laparoscopic cholecystectomy for cholelithiasis in patients with liver cirrhosis. 61 54
18493357 1995
9
Splanchnic Vein Thrombosis in Liver Cirrhosis After Splenectomy or Splenic Artery Embolization: A Systematic Review and Meta-Analysis. 61
33687650 2021
10
The spectrum of splenic complications in patients with sickle cell disease in Africa: a systematic review. 61
33161568 2021
11
Splenic non-infarction volume determines a clinically significant hepatic venous pressure gradient response to partial splenic embolization in patients with cirrhosis and hypersplenism. 61
33629147 2021
12
Short- and long-term outcomes of 486 consecutive laparoscopic splenectomy in a single institution. 61
33787621 2021
13
Splenectomy improves liver fibrosis via tumor necrosis factor superfamily 14 (LIGHT) through the JNK/TGF-β1 signaling pathway. 61
33654222 2021
14
Is simultaneous partial splenectomy during pediatric liver transplantation safe and effective for severe hypersplenism? A prospective cohort study. 61
33746054 2021
15
An unusual presentation of portal vein thrombosis in a 2-year-old girl. 61
32829990 2021
16
Thrombocytopenia in Virus Infections. 61
33672766 2021
17
Efficacy and safety of laparoscopic splenectomy for hypersplenism secondary to portal hypertension after transjugular intrahepatic portosystemic shunt. 61
33573590 2021
18
Evaluation of perfusion changes using a 2D Parametric Parenchymal Blood Flow technique with automated vessel suppression following partial spleen embolization in patients with hypersplenism and portal hypertension. 61
33607830 2021
19
Simultaneous partial splenectomy during liver transplantation for advanced cirrhosis patients combined with severe splenomegaly and hypersplenism. 61
33642835 2021
20
Abnormally Short Erythrocyte LifeSpan in Three Patients with Primary Myelofibrosis Despite Successful Control of Splenomegaly. 61
32950178 2021
21
Partial splenic embolization combined with endoscopic therapies and NSBB decreases the variceal rebleeding rate in cirrhosis patients with hypersplenism: a multicenter randomized controlled trial. 61
33638769 2021
22
Dialysis-related thrombocytopenia: a case report. 61
33657204 2021
23
Splenic embolization to continue chemotherapy in a child with hypersplenism-related thrombocytopenia. 61
32790133 2021
24
Case report: Trans-papillary free stenting of the cystic duct and of the common bile duct in a double biliary ducts anastomoses of a right lobe living donor transplantation. 61
33468113 2021
25
A Rare Quadruple Association: Fibromuscular Dysplasia, Giant Splenic Artery Aneurysm, Extrahepatic Portal Hypertension, and Hypersplenism. 61
33603311 2021
26
Platelet safety range before splenectomy for hypersplenism: based on 244 cases of splenectomy in hepatolenticular degeneration patients. 61
33639693 2021
27
Splenectomy before hepatectomy for patients with hepatocellular carcinoma and hypersplenism: A retrospective study. 61
33530224 2021
28
[Progress in the diagnosis and treatment of idiopathic non-cirrhotic portal hypertension]. 61
33541029 2021
29
Portosystemic shunt for portal hypertension after Kasai operation in patients with biliary atresia. 61
33201302 2021
30
Comprehensive Analysis of Long-term Splenic Volume Changes in Pediatric Liver Transplant Patients: Does It Correlate With Adverse Graft Outcomes? 61
32919802 2021
31
Bevacizumab Does Not Influence the Efficacy of Partial Splenic Embolization in the Management of Chemotherapy-Induced Hypersplenism. 61
32680816 2020
32
Pretransplantation splenomegaly frequently persists after liver transplantation and can manifest as hypersplenism and graft fibrosis - a retrospective study. 61
33166011 2020
33
Short-term Effects of Hepatic Arterial Buffer Responses Induced by Partial Splenic Embolization on the Hepatic Function of Patients with Cirrhosis According to the Child-Pugh Classification. 61
33281164 2020
34
A case of LGL leukemia with paucity of erythropoiesis. 61
33363975 2020
35
[Niemann-Pick disease type B with hypersplenism and cleft palate]. 61
33333704 2020
36
Noninvasive imaging assessment of portal hypertension. 61
32926209 2020
37
Successful Simultaneous Anatomic Subtotal Splenectomy During Pediatric Living-Donor Liver Transplantation: A Case Report. 61
32414607 2020
38
Effects of laparoscopic splenectomy and azygoportal disconnection on liver synthesis function and cirrhosis: a 2-year prospective study. 61
31820157 2020
39
Improvement of human platelet aggregation post-splenectomy with paraesophagogastric devascularization in chronic hepatitis B patients with cirrhotic hypersplenism. 61
31851564 2020
40
Endovascular Trapping of a Giant Splenic Artery Aneurysm by Liquid Embolic in a Case of EHPVO with Hypersplenism with a Complicated Post Procedure Course. 61
33227466 2020
41
Expanded circulating follicular dendritic cells facilitate immune responses in chronic HBV infection. 61
33160362 2020
42
Development of an Eye-Tracking Image Manipulation System for Angiography: A Comparative Study. 61
33158704 2020
43
The spleen size in patients undergoing hemodialysis. 61
33079128 2020
44
[Association of Semaphorin 3A with thrombocytopenia in systemic lupus erythematosus]. 61
33047725 2020
45
Frequency and Etiology of Pancytopenia in Patients Admitted to a Tertiary Care Hospital in Karachi. 61
33224653 2020
46
The Efficacy of Cladribine (2-CdA) in Advanced Systemic Mastocytosis. 61
33093752 2020
47
[Role of hepatic venous pressure gradient in the overall management process of portal hypertension]. 61
33053970 2020
48
Laparoscopic splenectomy via the spleen bed in combination with selective esophagogastric devascularization for patients with cirrhotic portal hypertension: a single-institution experience. 61
32904588 2020
49
Ineffective communication equals no communication: a case report of splenic hyperfunction combined with pseudothrombocytopenia. 61
32819117 2020
50
Durability of partial splenic artery embolization on platelet counts for cancer patients with hypersplenism-related thrombocytopenia. 61
32314004 2020
Sources

Variations for Hypersplenism

About this section
Sources

Expression for Hypersplenism

About this section
Search GEO for disease gene expression data for Hypersplenism.
Sources

Pathways for Hypersplenism

About this section

Pathways related to Hypersplenism according to GeneCards Suite gene sharing:

(show top 50) (show all 54)
# Super pathways Score Top Affiliating Genes
1
ERK Signaling 63
Show member pathways
 13.82 THPO PIK3R1 LTA IL4 EGF CSF3
2
PEDF Induced Signaling 63
Show member pathways
 13.49 TLR4 THPO PIK3R1 LTA IL4 IFNG
3
TGF-Beta Pathway 63
Show member pathways
 13.47 THPO PIK3R1 LTA IL4 IFNG F2
4
Cytokine Signaling in Immune system 65
Show member pathways
 13.34 PIK3R1 LTA IL4 IFNG EGF CSF3
5
Response to elevated platelet cytosolic Ca2+ 65
Show member pathways
 13.31 THPO SERPINC1 PIK3R1 F2 EGF CSF2
6
Akt Signaling 63
Show member pathways
 13.3 TLR4 THPO PIK3R1 LTA IL4 EGF
7
PAK Pathway 63
Show member pathways
 13.23 THPO PIK3R1 LTA IL4 EGF CSF3
8
p70S6K Signaling 63
Show member pathways
 13.05 THPO PIK3R1 IL4 F2 EGF BMP6
9
PI3K-Akt signaling pathway 36
Show member pathways
 12.97 TLR4 PIK3R1 IL4 EPO EGF CSF3
10
Allograft rejection 1 36
Show member pathways
 12.85 LTA IL4 IFNG FOXP3 CD4
11
Pathways in cancer 36
12.84 PIK3R1 IL4 IFNG F2 EPO EGF
12
Immune response NFAT in immune response 23
Show member pathways
 12.64 REL PIK3R1 IL4 IFNG CD4
13
NF-KappaB Family Pathway 63
Show member pathways
 12.64 TLR4 THPO REL PIK3R1 LTA EGF
14
4-1BB Pathway 63
Show member pathways
 12.63 REL PIK3R1 LTA IFNG EGF CD4
15
Th17 cell differentiation 36
Show member pathways
 12.59 TLR4 IL4 IFNG FOXP3 CD4
16
Immune response IL-23 signaling pathway 23
Show member pathways
 12.58 REL PIK3R1 IFNG F2 CD4
17
T cell receptor signaling pathway 36
Show member pathways
 12.4 TLR4 REL PIK3R1 IL4 IFNG EGF
18
Human T-cell leukemia virus 1 infection 36
12.35 PIK3R1 LTA CSF2 CD4
19
Folate Metabolism 1
Show member pathways
 12.34 IL4 IFNG F2 ALB
20
IL-17 Family Signaling Pathways 64
Show member pathways
 12.34 REL IL4 IFNG CSF3 CSF2
21
Immune response IFN alpha/beta signaling pathway 23
Show member pathways
 12.26 THPO LTA IL4 IFNG BMP6
22
Colorectal Cancer Metastasis 63
12.18 TLR4 PIK3R1 IFNG EGF
23
Bacterial infections in CF airways 23
Show member pathways
 12.18 TLR4 REL IL4 IFNG
24
IL12-mediated signaling events 1
Show member pathways
 11.99 REL IL4 IFNG CD4
25
JAK-STAT signaling pathway 36
Show member pathways
 11.96 THPO PIK3R1 IL4 IFNG EPO EGF
26
Amoebiasis 36
11.93 TLR4 PIK3R1 IFNG CSF2
27
HIF-1 signaling pathway 36
11.93 TLR4 PIK3R1 IFNG EPO EGF
28
Mesenchymal Stem Cell Differentiation Pathways and Lineage-specific Markers 64
11.87 THPO EGF BMP6
29
Th17 Differentiation Pathway 64
Show member pathways
 11.87 TLR4 IL4 IFNG CD4
30
Rheumatoid arthritis 36
11.86 TLR4 IFNG CSF2
31
Glucocorticoid receptor regulatory network 1
11.8 IL4 IFNG CSF2
32
Innate Lymphoid Cell Differentiation Pathways 64
11.8 LTA IL4 IFNG CD4
33
Cytokine production by Th17 cells in CF (Mouse model) 23
Show member pathways
 11.8 TLR4 REL FOXP3 CSF3 CSF2
34
Hematopoietic cell lineage 36
11.79 THPO IL4 EPO CSF3 CSF2 CD4
35
Th1 Differentiation Pathway 64
Show member pathways
 11.77 TLR4 LTA IFNG CD4
36
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.77 IL4 IFNG FOXP3 CSF2
37
Dendritic Cells Developmental Lineage Pathway 64
11.75 IFNG CSF2 CD4
38
IL2 signaling events mediated by PI3K 1
Show member pathways
 11.7 PIK3R1 LTA IL4 FOXP3
39
IgA-Producing B Cells in the Intestine 64
11.69 TLR4 LTA IL4 FOXP3
40
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.68 REL IFNG CSF2
41
IL4-mediated signaling events 1
11.67 PIK3R1 LTA IL4
42
Lung fibrosis 1
11.65 IL4 EGF CSF3 CSF2
43
Transcription_NF-kB signaling pathway 23
11.6 TLR4 REL LTA
44
Cellular Transformation by HTLV1 63
Show member pathways
 11.57 REL LTA IFNG
45
Malaria 36
11.55 TLR4 IFNG CSF3
46
Interleukin-10 signaling 65
11.54 IL4 CSF3 CSF2
47
MSP-RON Signaling 63
11.53 TLR4 PIK3R1 IFNG
48
Hematopoietic Stem Cell Differentiation 1
11.53 EPO CSF3 CSF2
49
Th2 Differentiation Pathway 64
11.49 IL4 IFNG FOXP3 CD4
50
IL-15 Signaling Pathways and their Primary Biological Effects in Different Immune Cell Types 64
Show member pathways
 11.37 IFNG FOXP3 CSF2
Sources

GO Terms for Hypersplenism

About this section

Cellular components related to Hypersplenism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 THPO SERPINC1 LTA IL4 IFNG F2
2 extracellular space GO:0005615 9.44 THPO SERPINC1 LTA IL4 IFNG GPT

Biological processes related to Hypersplenism according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.19 TLR4 THPO PIK3R1 LTA IL4 EPO
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.14 TLR4 REL PIK3R1 IL4 FOXP3 CSF3
3 positive regulation of transcription, DNA-templated GO:0045893 10.07 REL IL4 FOXP3 EPO EGF CD4
4 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.92 TLR4 THPO EPO CD4
5 positive regulation of protein phosphorylation GO:0001934 9.91 THPO IFNG F2 CD4
6 positive regulation of protein kinase B signaling GO:0051897 9.91 THPO PIK3R1 EGF CSF3
7 cytokine-mediated signaling pathway GO:0019221 9.91 PIK3R1 IL4 CSF3 CSF2 CD4
8 response to lipopolysaccharide GO:0032496 9.88 TLR4 LTA FOXP3 EPO
9 positive regulation of tumor necrosis factor production GO:0032760 9.82 TLR4 PIK3R1 IFNG
10 response to nutrient GO:0007584 9.81 SERPINC1 LTA EPO
11 negative regulation of tumor necrosis factor production GO:0032720 9.81 TLR4 IL4 FOXP3
12 positive regulation of gene expression GO:0010628 9.8 TLR4 IL4 IFNG FOXP3 EGF CSF2
13 negative regulation of neuron death GO:1901215 9.79 REL EPO CSF3
14 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.76 EGF CSF3 CD4 BMP6
15 T cell activation GO:0042110 9.72 IL4 FOXP3 CD4
16 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.71 IL4 IFNG EPO CSF2
17 negative regulation of osteoclast differentiation GO:0045671 9.67 TLR4 PIK3R1 IL4
18 regulation of blood coagulation GO:0030193 9.65 SERPINC1 F2
19 negative regulation of interleukin-17 production GO:0032700 9.65 TLR4 IFNG FOXP3
20 cellular response to granulocyte macrophage colony-stimulating factor stimulus GO:0097011 9.64 CSF2 CD4
21 negative regulation of T-helper 17 cell differentiation GO:2000320 9.63 IL4 FOXP3
22 macrophage differentiation GO:0030225 9.61 IFNG CSF2 CD4
23 positive regulation of cellular respiration GO:1901857 9.58 IL4 IFNG
24 neuroinflammatory response GO:0150076 9.57 IL4 IFNG
25 positive regulation of interleukin-23 production GO:0032747 9.56 IFNG CSF2
26 immune response GO:0006955 9.56 TLR4 LTA IL4 IFNG CSF3 CSF2
27 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.55 PIK3R1 F2 EPO EGF CSF3
28 macrophage activation GO:0042116 9.54 TLR4 IL4 CSF2
29 negative regulation of chronic inflammatory response GO:0002677 9.52 IL4 FOXP3
30 positive regulation of MHC class II biosynthetic process GO:0045348 9.5 TLR4 IL4 IFNG
31 positive regulation of cell proliferation GO:0008284 9.28 THPO IL4 IFNG F2 EPO EGF

Molecular functions related to Hypersplenism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.55 TLR4 THPO LTA F2 CD4
2 growth factor activity GO:0008083 9.5 THPO IL4 F2 EGF CSF3 CSF2
3 cytokine activity GO:0005125 9.23 THPO LTA IL4 IFNG EPO CSF3
Sources

Sources for Hypersplenism

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....